Étiquette : Alzheimer’s disease

AGENT

by jbertholdin Medtech

AgenT

About the company

AgenT, founded in 2018, is on a mission to defeat Alzheimer’s by targeting the silent phase. Leveraging a groundbreaking multi-omics approach combined with A.I., they have identified new blood biomarkers deregulated from the earliest stages of the disease. Using this proprietary database, they have developed two blood tests, B-HEALED™ and B-AHEAD™, for early and precise detection during the pre-dementia stages, unlocking the future of precision medicine. Their innovation is crucial in the era of emerging treatments like Leqembi, enabling detection and treatment of Alzheimer’s before cognitive decline manifests.

By embracing precision medicine and expanding the biomarker toolkit, AgenT is positioning themselves for the next leap in Alzheimer’s treatment, ensuring patients receive the right therapy at the right time.

About the solution


Traditional Alzheimer’s tests detect brain amyloid levels—a risk factor, not a definitive diagnostic marker, leading to up to 25% false positives among mild cognitive impairment (MCI) patients. AgenT’s B-HEALED test dramatically reduces this false positive rate by two-thirds with its non-invasive, cost-effective, and scalable blood test, offering a breakthrough in Alzheimer’s diagnostics.

By accurately identifying MCI patients who can benefit from early intervention with disease-modifying treatments, their test ensures timely and precise therapy to slow Alzheimer’s progression effectively, without exposing non-Alzheimer’s patients to unnecessary drug side effects.

Website
Key information

–  Therapeutic areas: Alzheimer’s Disease, CNS

–  Based in: Paris (FRANCE)

–  Employees: 1-10

–  Created in: 2018

BRAINTALE

by jbertholdin Digital Health, Medtech

BRAINTALE

About the company

BrainTale is an innovative medtech company deciphering white matter to enable faster drug development and better brain care with clinically validated prognostic solutions. With non-invasive, sensitive and reliable measurements of white matter microstructure alterations, BrainTale offers a digital biomarkers platform to support clinical development programs and decision-making in clinical routine.

BrainTale enables the identification of patients at risk, early diagnosis and monitoring of disease progression and the effectiveness of treatments in neurology, in particular for demyelinating diseases such as Multiple Sclerosis and neurodegenerative diseases such as Alzheimer’s Diseases. Based on more than 15 years of research and development, BrainTale’s products are developed to meet the medical needs and expectations of pharma companies and healthcare professionals for the benefit of patients. 

About the solution

BrainTale’s solutions enable access to diffusion MRI markers for drug development and patient care, through a unique technology that enables calibration and standardization of MRI diffusion parameters in a multidevice and multicenter setting. Thus, BrainTale offers quantification of white matter tissue, especially fiber density, axonal degeneration and myelin content, with unlimited potential to support clinical development programs through accurate patient selection and stratification at inclusion, and evaluation of treatment efficacy with highly sensitive and robust biomarkers.

Website
Key information

–  Therapeutic areas: Neuroscience, Neurology, Alzheimer’s Disease, Multiple Sclerosis, Traumatic Brain Injury, Rare demyelinating diseases

–  Based in: Paris & Strasbourg (FRANCE)

–  Employees: 11 – 50

–  Created in: 2018

ALZPROTECT

by jbertholdin Biotech, Pharma

ALZPROTECT

About the company

Alzprotect, established in 2007 in Lille, France, focuses on creating therapies to slow or halt neurodegenerative diseases and rejuvenate brain function. Alzprotect is dedicated to innovating in the neurodegenerative field. The company holds 4 international patent families for its developed drugs and their global indications.

About the solution

Alzprotect is making strides with AZP2006 (EZEPROGIND), a novel oral synthetic molecule aimed at enhancing lysosome homeostasis by regulating Progranulin and its chaperone protein, Prosaposin. Unlike traditional treatments that target symptoms like amyloid peptides or Tau protein, AZP2006 focuses on the root processes of neurodegeneration. It has shown promising results in reducing amyloid peptide secretion, lowering hyperphosphorylated Tau protein levels, and decreasing neuroinflammation, thus offering a comprehensive treatment approach. Granted « orphan drug » status in Europe and the US for Progressive Supranuclear Palsy (PSP), its safety and efficacy have been proven in human trials, paving the way for Phase 2B/3 trials for PSP and future applications in Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis.

Website
Key information

–  Therapeutic areas: Neurodegenerative diseases, Alzheimer’s disease, Progressive Nuclear Palsy, Parkinson’s disease

–  Based in: Loos (FRANCE), Boston (US)

–  Employees: 1 – 10

– Created in: 2007